Elham Fatehi
Biographic Data
| ID | 4237839 |
|---|---|
| NAME | Elham Fatehi |
| GIVEN NAMES | Elham |
| FAMILY NAME | Fatehi |
| SIGNATURE | FATEHI E |
| AFFILIATIONS | Johnson & Johnson (United States) |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
Introduction Racial/ethnic minority populations in the US have a high burden of pulmonary arterial hypertension (PAH). Objective To evaluate demographics, disease characteristics, prescribing patterns, hospitalization, and survival in racial/ethnic groups in the SPHERE registry. Methods SPHERE was a US, multicenter, prospective, observational registry of adults prescribed selexipag in clinical practice (November 2016-March 2020). Follow-up was ≤ …
No prominent works on this page.
Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
Introduction Racial/ethnic minority populations in the US have a high burden of pulmonary arterial hypertension (PAH). Objective To evaluate demographics, disease characteristics, prescribing patterns, hospitalization, and survival in racial/ethnic groups in the SPHERE registry. Methods SPHERE was a US, multicenter, prospective, observational registry of adults prescribed selexipag in clinical practice (November 2016-March 2020). Follow-up was ≤ …
Adverse effect (1 works) · Epidemiology (1 works) · Ethnic group (1 works) · Internal Medicine (1 works) · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (1 works) · Medicine (1 works) · Observational study (1 works) · Pulmonary Hypertension Research and Treatments (1 works)